Cargando…

Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms

BACKGROUND: Immunohistochemical (IHC) PD-L1 expression is commonly employed as predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC). However, IHC evaluation methods are non-uniform and further studies are needed to optimize clinical utility. METHODS: We compared the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sigurjonsdottir, Gudbjörg, De Marchi, Tommaso, Ehinger, Anna, Hartman, Johan, Bosch, Ana, Staaf, Johan, Killander, Fredrika, Niméus, Emma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566164/ https://www.ncbi.nlm.nih.gov/pubmed/37817263 http://dx.doi.org/10.1186/s13058-023-01724-2

Ejemplares similares

Molecular analyses of triple-negative breast cancer in the young and elderly
por: Aine, Mattias, et al.
Publicado: (2021)

Correction to: Molecular analyses of triple-negative breast cancer in the young and elderly
por: Aine, Mattias, et al.
Publicado: (2021)

Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trial
por: Stenmark Tullberg, Axel, et al.
Publicado: (2023)

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
por: Glodzik, Dominik, et al.
Publicado: (2020)

Low levels of WRAP53 predict decreased efficacy of radiotherapy and are prognostic for local recurrence and death from breast cancer: a long‐term follow‐up of the SweBCG91RT randomized trial
por: Egelberg, Moa, et al.
Publicado: (2023)

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2021)

Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer
por: Li, Yijin, et al.
Publicado: (2021)

SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3
por: Pang, Jia-Min B., et al.
Publicado: (2021)

Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast‐conserving surgery: a long‐term follow‐up of the SweBCG91‐RT randomised trial
por: Sjöström, Martin, et al.
Publicado: (2020)

Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer
por: Lee, Seung Eun, et al.
Publicado: (2020)

SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
por: Baek, Seung Ho, et al.
Publicado: (2022)

PD-L1 Testing in Urothelial Carcinoma: Analysis of a Series of 1401 Cases Using Both the 22C3 and SP142 Assays
por: Evans, Harriet, et al.
Publicado: (2022)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
por: Vennapusa, Bharathi, et al.
Publicado: (2019)

Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up
por: Tutzauer, Julia, et al.
Publicado: (2022)

Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer
por: Xu, Haipeng, et al.
Publicado: (2017)

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
por: Maule, Jake G, et al.
Publicado: (2022)

PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
por: Cha, Yoon Jin, et al.
Publicado: (2021)

PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers
por: Compérat, Eva, et al.
Publicado: (2021)

Comments on the Article by Miura et al.: “Comparable Clinical Benefit Between Different Subsets Selected by PD-L1 22C3 and SP142 Tests”
por: Yatabe, Yasushi
Publicado: (2023)

Effect of storage time of paraffin sections on the expression of PD-L1 (SP142) in invasive breast cancer
por: He, Jiankun, et al.
Publicado: (2023)

Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
por: Krawczyk, Paweł, et al.
Publicado: (2017)

Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group
por: Van Bockstal, Mieke R., et al.
Publicado: (2021)

Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
por: Stenmark Tullberg, Axel, et al.
Publicado: (2023)

SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3
por: Nakahama, Kenji, et al.
Publicado: (2022)

Whole-genome-sequencing of triple negative breast cancers in a population-based clinical study
por: Staaf, Johan, et al.
Publicado: (2019)

Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors
por: Sjöström, Martin, et al.
Publicado: (2018)

Relationship between SP142 PD-L1 Expression and (18)F-FDG Uptake in Non-Small-Cell Lung Cancer
por: Zhao, Long, et al.
Publicado: (2020)

Inter- and Intra-Observer Agreement of PD-L1 SP142 Scoring in Breast Carcinoma—A Large Multi-Institutional International Study
por: Zaakouk, Mohamed, et al.
Publicado: (2023)

Proteogenomic Workflow Reveals Molecular Phenotypes Related to Breast Cancer Mammographic Appearance
por: De Marchi, Tommaso, et al.
Publicado: (2021)

PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N)
por: Ma, Jing, et al.
Publicado: (2018)

MTNR1B G24E Variant Associates With BMI and Fasting Plasma Glucose in the General Population in Studies of 22,142 Europeans
por: Andersson, Ehm A., et al.
Publicado: (2010)

Making Breast Cancer Molecular Subtypes Robust?
por: Staaf, Johan, et al.
Publicado: (2014)

Consensus of gene expression phenotypes and prognostic risk predictors in primary lung adenocarcinoma
por: Ringnér, Markus, et al.
Publicado: (2016)

Tumor purity adjusted beta values improve biological interpretability of high-dimensional DNA methylation data
por: Staaf, Johan, et al.
Publicado: (2022)

Coulomb Excitation of $^{142}$Xe
por: Henrich, C, et al.
Publicado: (2018)

142nd SPSC Meeting
Publicado: (2021)

142nd LHCC Meeting
Publicado: (2020)

PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy
por: Suzuki, Yuka, et al.
Publicado: (2020)

Triple DC SP2T
por: Bento, J
Publicado: (2000)

The functional impact of G protein-coupled receptor 142 (Gpr142) on pancreatic β-cell in rodent
por: Al-Amily, Israa Mohammad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hoocq6itd3c5bdo5jleasiuu8r